Mirxes Holding Company Limited (HKG: 2629) announced the signing of a Memorandum of Understanding (MOU) with the National Cancer Institute of Thailand to establish a strategic collaboration in colorectal cancer screening. Under the agreement, the Institute will prospectively enroll 2,000 subjects who have tested positive on a fecal immunochemical test (FIT) to evaluate Mirxes’s blood‑based colorectal cancer early screening test as a precision triage tool – an initiative directly supporting Thailand’s goal of reducing cancer mortality under its “Cancer Moonshot 2056” program.
Collaboration Milestone
| Item | Detail |
|---|---|
| Parties | Mirxes Holding Company Limited (HKG: 2629); National Cancer Institute of Thailand |
| Agreement Type | Memorandum of Understanding (MOU) – strategic collaboration |
| Field | Colorectal cancer screening |
| Signing Date | 15 Oct 2026 |
| Study Design | Prospective enrollment of 2,000 FIT‑positive subjects |
| Objective | Evaluate Mirxes’s blood‑based colorectal cancer early screening test as a precision triage tool |
| Policy Alignment | Thailand’s “Cancer Moonshot 2056” initiative – reducing cancer mortality |
| Regulatory Footprint | Three Mirxes diagnostic tests approved by the Thai FDA to date |
Study Design & Clinical Rationale
- Population: 2,000 subjects who have tested positive on a fecal immunochemical test (FIT) – the standard first‑line non‑invasive screening modality – will be prospectively enrolled by the National Cancer Institute of Thailand.
- Role of the Blood Test: Mirxes’s blood‑based colorectal cancer early screening test will be evaluated as a precision triage tool positioned downstream of FIT positivity.
- Risk Stratification Logic: Through risk stratification, the collaboration aims to prioritize colonoscopy resources for high‑risk populations – addressing a central bottleneck in screening programs, where limited endoscopy capacity constrains follow‑up of FIT‑positive individuals.
- Public Health Objective: The initiative directly supports Thailand’s “Cancer Moonshot 2056” goal of reducing cancer mortality, aligning a commercial diagnostic with national cancer‑control policy.
Company Profile – Mirxes in Thailand
- Listed Status: Mirxes Holding Company Limited trades on the Hong Kong Stock Exchange under ticker HKG: 2629.
- Regulatory Track Record: To date, three of Mirxes’s diagnostic tests have been approved by the Thai Food and Drug Administration (Thai FDA) – establishing a regulatory foundation for the collaboration.
- Strategic Positioning: The MOU extends Mirxes’s footprint in Southeast Asian population‑level cancer screening, leveraging a partnership with Thailand’s national cancer authority.
Market Impact & Outlook
- Screening Pathway Integration: A validated blood‑based triage layer between FIT and colonoscopy could materially improve the efficiency of national colorectal cancer screening programs in resource‑constrained settings.
- Government Partnership Signal: Collaboration with the National Cancer Institute of Thailand under the “Cancer Moonshot 2056” umbrella positions Mirxes as a policy‑aligned partner in Thailand’s cancer‑control agenda.
- Evidence Generation Watch: Investors will follow enrollment progress and readouts from the 2,000‑subject prospective study (timelines not disclosed), which would generate real‑world triage performance data for the blood‑based test.
- Regional Expansion Potential: Successful evaluation in Thailand could support broader adoption of Mirxes’s Thai FDA‑approved diagnostic portfolio across Southeast Asia (no further market commitments announced).
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the collaboration between Mirxes and the National Cancer Institute of Thailand, including subject enrollment, evaluation outcomes for the blood‑based colorectal cancer screening test, and potential public health impact under the “Cancer Moonshot 2056” initiative. Actual results may differ materially due to risks including study execution, clinical performance of the test, regulatory developments, and government program priorities. An MOU establishes a framework for collaboration and does not guarantee subsequent commercial or regulatory outcomes.-Fineline Info & Tech
